Literature DB >> 10591035

Anisodamine as an effective drug to treat snakebites.

Q B Li1, R Pan, G F Wang, S X Tang.   

Abstract

Anisodamine is a natural alkaloid drug isolated from the plant Anisodus tanguticus growing in western China. The chemical structure and pharmacological action are just like the cholinergic receptor blocking agents atropine or scopolamine. The specific characteristic of the drug is being able to relieve the dangerous situation of microcirculatory failure, especially in case of DIC or renal failure. The prognosis of the patients will be quite good. Another characteristic of the drug is that no serious toxic reaction occurs even in successive doses given intravenously up to 500 mg a day. This is about fifty times greater than a common dose of 10 mg. Since we begin with the drug as a routine medication for the symptomatic treatment of renal failure, DIC bleeding, and microcirculatory failure, we should say that the specific antivenin and anisodamine are two treasure drugs for snakebites.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591035

Source DB:  PubMed          Journal:  J Nat Toxins        ISSN: 1058-8108


  6 in total

Review 1.  Possible role for anisodamine in organophosphate poisoning.

Authors:  Arik Eisenkraft; Avshalom Falk
Journal:  Br J Pharmacol       Date:  2016-04-22       Impact factor: 8.739

2.  Anisodamine potently inhibits SARS-CoV-2 infection in vitro and targets its main protease.

Authors:  Wei Wei; Ni Kong; Meng-Zhen Liu; Ting Han; Jun-Feng Xu; Chong Liu
Journal:  Biochem Biophys Res Commun       Date:  2022-05-13       Impact factor: 3.322

3.  Do herbal medicines have potential for managing snake bite envenomation?

Authors:  Y K Gupta; S S Peshin
Journal:  Toxicol Int       Date:  2012-05

4.  Anisodamine Ameliorates Hyperkalemia during Crush Syndrome through Estradiol-Induced Enhancement of Insulin Sensitivity.

Authors:  Jian-Guang Yu; Bo-Shi Fan; Jin-Min Guo; Yun-Jie Shen; Ye-Yan Hu; Xia Liu
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

5.  Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19.

Authors:  Zhen Qin; Kefa Xiang; Ding-Feng Su; Yang Sun; Xia Liu
Journal:  Front Immunol       Date:  2021-02-08       Impact factor: 7.561

6.  Activation of α7 Nicotinic Acetylcholine Receptor Decreases On-site Mortality in Crush Syndrome through Insulin Signaling-Na/K-ATPase Pathway.

Authors:  Bo-Shi Fan; En-Hui Zhang; Miao Wu; Jin-Min Guo; Ding-Feng Su; Xia Liu; Jian-Guang Yu
Journal:  Front Pharmacol       Date:  2016-03-29       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.